Methamphetamine-dependence
29
7
10
13
Key Insights
Highlights
Success Rate
87% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 15/100
6.9%
2 terminated out of 29 trials
86.7%
+0.1% vs benchmark
10%
3 trials in Phase 3/4
69%
9 of 13 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 13 completed trials
Clinical Trials (29)
Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder
Inflammation in Methamphetamine and STIs (IMSTI)
Glutide for Ending Methamphetamine
PRevention Of Methamphetamine Use Among Postpartum Women Trial (PROMPT)
MHealth Incentivized Adherence Plus Patient Navigation
Effect of Methamphetamine on Residual Latent HIV Disease Study
Feasibility of Long-term, High-dose Stimulant for Methamphetamine Use Disorder
Encouraging Abstinence Behavior in a Drug Epidemic: Optimizing Dynamic Incentives
Clinical Trial of High Dose Lisdexamfetamine and Contingency Management in MA Users
Pilot Study of the Effect of Ibudilast on Neuroinflammation in Methamphetamine Users
Pilot TMS for Methamphetamine Use Disorder
The Human Stress Response in a Simulated ED Setting
Monthly Injectable BUP for MA Use Disorder (MURB) Trial
Role of Pavlovian Mechanisms for Control Over Substance Use
Effects of Genotype on Resting State Connectivity During Methamphetamine Administration
Multiple-Dose Study to Evaluate the Safety and Efficacy of IXT-m200
Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders
rTMS for Craving in Methamphetamine Use Disorder
Delivering Contingency Management in Outpatient Addiction Treatment
ACT for Methamphetamine Use Disorder in Women and Gender Non-Conforming Individuals